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Abstract: In near infrared fluorescence-guided surgical oncology, it is
challenging to distinguish healthy from cancerous tissue. One promising
research avenue consists in the analysis of the exogenous fluorophores’ life-
time, which are however in the (sub-)nanosecond range. We have integrated
a single-photon pixel array, based on standard CMOS SPADs (single-photon
avalanche diodes), in a compact, time-gated measurement system, named
FluoCam. In vivo measurements were carried out with indocyanine green
(ICG)-modified derivatives targeting the αvβ3 integrin, initially on a geneti-
cally engineered mouse model of melanoma injected with ICG conjugated
with tetrameric cyclic pentapeptide (ICG−E[c(RGD f K)4]), then on mice
carrying tumour xenografts of U87-MG (a human primary glioblastoma cell
line) injected with monomeric ICG−c(RGD f K). Measurements on tumor,
muscle and tail locations allowed us to demonstrate the feasibility of in vivo
lifetime measurements with the FluoCam, to determine the characteristic
lifetimes (around 500 ps) and subtle lifetime differences between bound
and unbound ICG-modified fluorophores (10% level), as well as to estimate
the available photon fluxes under realistic conditions.
© 2016 Optical Society of America
OCIS codes: (030.5260) Photon counting, Imaging systems; (170.2520) Fluorescence mi-
croscopy; (170.3650) Lifetime-based sensing; (170.3880) Medical and biological imaging;
(230.5160) Photodetectors.
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1. Introduction
Over the last 25 years, the treatment of cancer has made great progress. Using non-invasive
imaging technologies such as CT, MRI and PET, cancer can be detected at an early stage and
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can be removed either by open surgery or by employing minimally-invasive techniques such
as endoscopy or laparoscopy. The intra-operative clinical discrimination between tumor and
normal tissue is however mostly based on visual inspection and palpation. It is therefore far
from straightforward for the surgeon to ensure that during surgical operations the tumor is
removed completely with a sufficient tumor-free margin.
A promising development in this area is the use of exogenous near infrared (NIR) fluorescent
probes [1, 2]. Operating in the 700-900 nm wavelength window has the substantial advantage
of enabling deeper penetration in tissue (up to about 5-10 mm [3]) as well as reducing the
background due to the autofluorescence of (naturally occurring) endogenous fluorophores. The
corresponding intensity-based imaging techniques, some of which have already become com-
mercially available, are mostly based on standard CMOS or CCD cameras with high sensitivity
in the NIR and appropriate illumination engines [4–8].
There is nevertheless the need to overcome several limitations of intra-operative clinical,
wide-field intensity-based fluorescence imaging systems for surgical oncology. One promising
research avenue consists in the analysis of the fluorophore lifetime, which is typically in the
(sub)nanosecond range, whether in an imaging-based modality akin to Fluorescence Lifetime
Imaging (FLIM) as used in microscopy for example [9], or in a simpler (raster scanned) point
detection set-up. Fluorescence lifetime analysis does potentially offer a better differentiation
between fluorophores bound to cancer cells and those floating freely through the body or aggre-
gated in cysts. In addition, it allows minimizing the effect of photon scattering in thick layers of
sample, is insensitive, within reasonable limits [9], to fluorophore concentration variations, and
offers better discrimination from background signals such as from endogenous fluorophores.
The main disadvantages from the hardware perspective lie in the need for compact, high sensi-
tivity real-time capable sensors and algorithms, with the corresponding illumination engines.
While it is true that very few fluorescent markers are approved for routine clinical use -
notably IndoCyanine Green (ICG) in the NIR [10,11] - several are at present undergoing clinical
evaluation. ICG per se is not cancer specific but can be chemically conjugated, e.g. with an
Arg-Gly-Asp (RGD) peptide sequence so as to target cancer cells with much higher efficiency
[12, 13].
Fluorescence lifetime analysis systems have been created for in vivo preclinical applica-
tions [14]. Time domain systems employ a combination of raster scanned fast PMT coupled
with single point Time Correlated Single Photon Counting (TCSPC) systems [15–17], time-
gated intensified CCDs [18,19], or high-speed digitizers for direct sampling of the fluorescence
temporal decay [20]. Frequency domain systems have been reported as well [21, 22], usually
employing slower frequency modulation techniques [23].
We report here on the use of a novel class of sensors - digital single-photon avalanche diode
(SPAD) arrays implemented in standard CMOS technologies - towards in vivo fluorescence
lifetime analysis-based oncology applications in the NIR, relying on exogenous fluorophores.
These all solid state sensor arrays feature excellent single-photon timing resolution (in the order
of 100 ps for each pixel, potentially in parallel over all pixels), low power, compactness, low
voltage operation, and are amenable to mass production and therefore low cost. These features
are usually traded off against overall sensitivity, due to the need for more complex in-pixel
electronics and therefore somewhat reduced fill-factor.
An existing SPAD array was enhanced with a gating scheme, building the core of a compact
measurement system, named FluoCam [24, 25], capable of providing both intensity and life-
time data by scanning half the integral of the lifetime response in time steps as fine as 12.3 ps,
and accurately reconstructing it (Section 2). The step size can be adjusted to allow faster imag-
ing, with similar lifetime precision. The sensor was combined with a picosecond diode laser,
offering the possibility of studying sub-nanosecond fluorescence mechanisms as well as subtle
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lifetime differences between bound and unbound fluorophores. Finally, while the system is in-
deed capable of providing lifetime images, it was initially employed in a point detection set-up,
using data from all pixels for lifetime extraction, to maximise the photon yield.
After having tested the system against ICG solutions with known lifetimes (Section 3),
we carried out a series of in vitro tests, characterizing cultured melanoma cells labelled
with tumour-specific fluorescent probes, i.e. ICG conjugated with cyclic pentapeptide (ICG−
c(RGD f K)) (Section 4). We then moved to in vivo measurements (Section 5), studying a genet-
ically engineered mouse model of melanoma injected with ICG−E[c(RGD f K)4], as well as
mice carrying tumour xenografts of U87-MG - a human primary glioblastoma cell line - inject-
ed with ICG− c(RGD f K). This allowed us to demonstrate the feasibility of lifetime measure-
ments with the FluoCam and determine the characteristic lifetimes and available photon fluxes
under realistic conditions.
2. Description of the measurement system
The complete FluoCam system is composed of the parts shown in Fig. 1. The optical set-up
permits to focus the laser light as a mm-sized point onto the sample, in epi-illumination mode,
and to image the fluorescence emission at 835 nm. The illumination source is featured on the top
left; it is composed of a PiLas picosecond diode laser (100 MHz EIG1000AF pulse generator
and PIL080F laser head, Advanced Laser Diode Systems A.L.S. GmbH, Berlin, Germany),
generating 70 ps wide pulses (FWHM) at λ = 790 nm, with an average power of 1.7 mW
[I]. Two wavelength filters (775±25 nm [WF1] and 845±25 nm [WF2]) and a dichroic mirror
(810 nm [D]) specific for ICG fluorescence (filter set No 41030, Chroma Technology Corp.,
Bellows Falls, USA) allow suppressing background and source illumination. The fluorescence
light passing through the dichroic mirror is then focussed on the camera and integrated in two
counters.
The counter values are transmitted to the host PC through a USB connection. The delay of
the delay lines is set by the FPGA and incremented in steps of 12.3 ps (on average).
2.1. SPSD camera
The FluoCam is based on the single photon synchronous detection (SPSD) imager detailed
in [26]. It comprises 60×48 pixels implemented in 0.35 µm CMOS technology. Each pixel is
composed of a SPAD, two 8 bit counters (C0 and C2), and a high-frequency switch, as shown
in Fig. 2.
CLK
100 MHz
Sample SPSDchip
FPGA
Pulse
Generator
delay lines
power
regulator
USB
com.
reference CLK
100 MHz
C0/C2
delay
delayed CLK
bi-directional
USB data transfer
power supply
delay lines board
power board
Laser
WF1
L1
WF2
I
L2
camera and FPGA board
D
Fig. 1: Schematic overview of the FluoCam fluorescence imaging system composed of the SPSD single-photon
camera (on the right), and optical path (on the left), with lenses [L1/L2], wavelength filters [WF1/WF2] and
ps-based laser illumination source [I]. The laser illumination is reflected by the dichroic mirror [D] onto the
sample, whereas the fluorescence light passes through the dichroic due to the wavelength shift. The fluores-
cence light is integrated in the camera chip in counters C0/C2, whose data is transmitted to a host PC through
a USB interface. The delay is incremented in time steps as fine as 12.3 ps to cover the fluorescence response.
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Table 1: Overview of FluoCam characteristics at system, chip and pixel level.
System level Specification
System
System & Laser CLK [MHz] 100
Gating duration [ns] 5
Gating step [ps] ≥ 12.3
Matrix readout time [µs] 10.8
Frame acquisition time [s] ≤ 1
Chip
Size [mm2] 6.5×5.5
Pixel array 60×48
CMOS process [µm] 0.35
Pixel
Pixel pitch [µm] 85
Fill factor [%] 0.8
Photodetection Probability∗ @ 835 nm [%] 2
Dead time [ns] 40
Dark count rate @ 25◦C [cps] 400
∗ Photodetection Probability = Quantum efficiency × probability to trigger an avalanche.
The SPSD imager was originally developed for indirect time-of-flight 3D imaging, using low
frequency modulation. In the new fluorescence camera (FluoCam), the system was modified so
as to use a precise time-based gating technique which allows the complete fine reconstruction
of a fluorescence signal.
An overview of the SPSD-based FluoCam specifications is provided in Table 1. The system is
air cooled (from an initial temperature of 40◦C down to approximately 25◦C) so as to decrease
the SPAD intrinsic noise, or DCR (dark count rate), by a factor of 3 to about 400 cps, and
increase the resolution of the delay lines (from 12.6 to 12.3 ps) [27, pp. 71-73].
The complete photodetection system is shown in more detail in Fig. 2, from the assembled
camera down to pixel level. It is composed of a camera driven by an FPGA and several discrete
electronic components in three compact PCB modules of roughly 6×6 cm, resulting in a total
system size smaller than 7×7×6 cm3. One PCB features the SPSD camera itself [26] and
the FPGA (Altera Cyclone II EP2C35U484C8N), a second the delay lines (2× MC10EP195,
cascaded), and a third the power regulators (AXH003A0X). A cooling system is added on the
exterior of the camera.
High timing resolution is possible by means of a gating scheme controlled by delay lines
with a resolution of approximately 12.3 ps after correction for non-linearities (see Fig. 5(a)).
This allows parallel multi-channel analysis with a typical single-photon timing resolution in the
order of 100 ps.
2.2. Lifetime measurement principle
The time-gated fluorescence lifetime reconstruction principle is illustrated in Fig. 3(a). A pi-
cosecond diode laser is triggered at 100 MHz to deliver light pulses to the sample. The 100 MHz
laser trigger signal is used as reference clock for the system and, after adding a delay, as a
counter switch.
The fluorescence emission density g(t) is approximated as a single-exponential function
g(t) = A · e− tτ [28, 29]; this is also justified by our final interest in lifetime contrast in a
clinical context, rather than measurement of absolute values. The normalized density function
is g(t) = 1τ · e−
t
τ . The white background contributed by dark counts and background noise
can be easily suppressed. The fluorescence measured by the SPAD camera can therefore be
represented by a convolution with the system’s Instrument Response Function IRF(t):
f (t) = g(t)∗ IRF(t) (1)
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Fig. 2: Detailed overview of the FluoCam camera system. Top: SPSD-based camera comprising (from left
to right) the SPSD chip with the FPGA control board, a delay lines board, and a power management board.
Bottom: chip micrograph and pixel schematic [24, 26].
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Fig. 3: (a) Time-gated fluorescence lifetime reconstruction principle as applied to the FluoCam measurements.
The laser trigger is used both as system clock and as trigger of the laser pulse. The laser pulse is pointed at the
sample which generates an exponential fluorescence response. This fluorescence response is finally measured
by the SPAD camera. Depending on the delay step (N×12.3 ps) between laser trigger and counter switch, the
events are stored in either the C0 or the C2 counter. (b) IRF and the fluorescence exponential convolved with
the IRF, i.e. the signal detected on the camera. (c) The integrated responses as measured by the camera in the
C0 counter.
This fluorescence signal f (t) is sensed by the SPAD-based camera as in Fig. 3(b), in which
events have been generated over a random exponential distribution (fluorescence response). The
counter switch, delayed in steps of roughly 12.3 ps with respect to the laser trigger, switches
alternatively between the counters C0 and C2 (high: C0, low: C2).
The normalized integrated counter responses C0 and C2 (as a function of the delay step t)
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are therefore:
C2IRF(t) =
∫ t
0
IRF(s)ds = IRF(t)∗w(t), t ≤ T (2a)
C2 f (t) =
∫ t
0
f (s)ds = f (t)∗w(t) = IRF(t)∗w(t)∗g(t)
= IRF(t)∗
(
1− e− tτ
)
, t ≤ T (2b)
C0(t) = 1−C2(t) (2c)
f (t) =
dC2 f (t)
dt
, t ≤ T (2d)
where the gate width T = 5 ns and w(t) is the window w(t) = 1 for 0≤ t ≤ T and w(t) = 0
otherwise. The ideal integrated counter responses C0(t) are depicted in Fig. 3(c). For simplicity,
Eq. (1) and (2) as well as Fig. 3 do not include noise. A more detailed error analysis, taking
into account noise sources such as Poisson, DCR or background noise, is outside the scope of
this paper; it can be performed by applying procedures similar to those published in [30–32].
One frame, i.e. one image at a fixed delay step, was mostly acquired in 1 s, after which
the delay step was incremented and a new 1 s acquisition started. Scanning the signal with
of up to 500 steps enables us to observe the fluorescence over 6.25 ns, which is sufficient to
study fluorescent probes with time constants of the order of 1 ns and below, like for ICG.
The acquisition time was initially maintained high on purpose, so as to perform analysis with
sufficient photon statistics. Therefore the total time required to measure one lifetime image is up
to about 10 minutes, during which the counts measured in C2 will increase (C0 will decrease)
over the acquired frames with increasing delay step. The result of such an acquisition is shown
in Fig. 5(b).
The total acquisition time can however be significantly reduced by either shortening the 1 s
frame acquisition time or by increasing the delay step size. Data gathered with a delay step up
to 8×, shows indeed similar lifetime extraction performance compared to the minimum delay
step, as will be later revealed in Fig. 8(c).
2.3. Signal processing and lifetime calculation
We investigated two complementary fluorescence lifetime processing approaches, namely iter-
ative Least Squares based fitting Methods (LSM) [33, 34] and Centre-of-Mass based approxi-
mation Methods (CMM) [32,35]. While it is true that CMM is inherently simpler and amenable
to real-time implementation in future high-sensitivity imagers, fitting methods proved to gener-
ate more accurate results that are less affected by the inherent noise of the SPAD-based system,
the average LSM standard deviation being over 50% smaller than that achievable with CMM
over the same set of measurement points. We will therefore focus on LSM results (except for
Fig. 8(a)) and the corresponding processing steps.
All measurements are achieved following the procedure detailed in Fig. 4, which is carried
out offline after the measurement on the 60×48 SPAD pixels, allowing the generation of two
dimensional lifetime data.
The first step in the procedure consists in the correction of the delay lines non-linearities
produced by redundant sequences in the delays. The delay transfer curve, as calibrated by the
manufacturer, is shown in Fig. 5(a). The correction procedure removes the points that are be-
low the delay that was already reached. A linear fit on the corrected data indicates a timing
resolution after correction of approximately 12.3 ps.
This procedure is applied on the raw signals as measured by the camera; Fig. 5(b) shows the
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Fig. 4: Signal processing chain (LSM fitting approach). Online measurements are carried out in parallel over
the whole imager, the offline processing is done sequentially.
200 400 600 800 1000
2
4
6
8
10
12
Delay code
C
al
ib
ra
te
d 
de
la
y 
[n
s]
Uncorrected transfer curve @ 25°C
Corrected transfer curve @ 25°C
(a)
0 500 1000 1500 2000 2500 3000 3500 4000 4500
0
0.5
1
1.5
2
2.5
x 105
Delay [ps]
P
ho
to
n 
co
un
ts
 [c
ps
]
C0
C2
Intensity
(b)
0 500 1000 1500 2000 2500 3000 3500
0
0.5
1
1.5
2
2.5
x 105
Delay [ps]
P
ho
to
n 
co
un
ts
 [c
ps
]
C0
C2
Intensity
(c)
0 500 1000 1500 2000 2500 3000 3500 4000
0
0.2
0.4
0.6
0.8
1
Delay [ps]
N
or
m
al
iz
ed
 p
ix
el
 s
ig
na
ls
200 kcps pixel @ 40°C
1 kcps pixel @ 40°C
200 kcps pixel @ 25°C
1 kcps pixel @ 25°C
(d)
Fig. 5: Signal processing steps: (a) correction of the non-linearities; the calibrated delay transfer curve (as
specified by the manufacturer) is corrected by removing redundant sequences in the delays. After fitting the
corrected transfer curve, a resolution of 12.3 ps is reached. (b) Raw counter signals C0 and C2 and the cor-
responding total intensity, featuring non-linearities and readout spikes. (c) Counter signals corrected for non-
linearities with the procedure from (a) and applying a moving average filter. (d) Final intensity normalized
C0 signals for both cooled / uncooled camera systems, the noise being significantly higher for the uncooled
system.
measured C0 and C2 counters as well as the total intensity C0+C2. The correction removes
those signal parts that are also redundant. Furthermore, a moving average filter of size 3 is
applied on the corrected results to smooth the data as shown in Fig. 5(c).
The last step is to normalize the signals with respect to the total intensity, i.e. C0m = C0C0+C2 ,
with C0m the normalized C0 signal. This procedure corrects the C0 signal for any change in
the total intensity over time, compensating for example for photobleaching. A set of samples
of C0m signals are shown in Fig. 5(d) for both cooled (25◦C) and uncooled (40◦C) data with
different pixel intensity. On the brightest pixel (250 kcps), the signals are almost identical.
However on the pixels with 1 kcps intensity, the signal from the temperature stabilized camera
is significantly less noisy.
The actual lifetime can then be extracted in two steps from C0m as detailed in Fig. 6. The
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Fig. 6: (a) IRF compensation simulation principle. Random events are generated with an exponential distribu-
tion (with lifetime τ) over the IRF, which determines the amount of events to be generated at each time step
(10×1 million per inserted lifetime). (b) For τ ranging from 0 to 1.2 ns, the procedure described in (a) is
applied, followed by a standard exponential fit (resulting in an extracted lifetime τt ), leading to a lifetime
correction look-up table.
standard LSM approach relies on minimizing the least square error ε given by:
ε ≡
M
∑
i=1
[
C0m(i)−C0t(i)
]2
(3)
with C0t being the theoretical C0 signal defined in Eq. (2c) and M the total number of time step
frames acquired in the measurement.
However, it is overly complicated and time consuming to calculate the convolution in each
iteration. Instead, we minimize first:
ε ≡
M
∑
i=1
[
C0m(i)−A · e−
i·∆
τm
]2
(4)
where ∆ is the time step (12.3 ps minimum) and τm is a time constant, calculated from the
measured data, but affected by an offset introduced by the IRF. τm can be obtained from a
standard exponential fit on the normalized C0 curves.
In order to calculate the aforementioned offset, and therefore be able to retrieve the original
lifetime τ in a second step, we first need to carry out the same procedure on C0t , minimizing
ε ≡
M
∑
i=1
[
C0t(i)−A · e−
i·∆
τt
]2
(5)
over a range of lifetime values and creating a look-up table of the extracted lifetime τt versus
the original τ of the exponential used to create C0t . The corresponding Monte Carlo simulation
procedure is schematically shown in Fig. 6(a). C0t is created by randomly distributing events
over exponential curves (with a given time constant τ) superimposed to the measured IRF.
The number of generated events depends on the normalized IRF area, i.e. most events will be
generated when the IRF is maximum. This signal is then integrated, forming the C0 and C2
counter signals. This simulation takes into account the actual IRF, DCR noise and jitter of the
FluoCam system.
The resulting table of τt versus the original τ is shown in Fig. 6(b) over lifetimes in the
range 0 to 1.2 ns. The influence of the IRF-introduced offset is significant, especially for lower
lifetimes, ranging from more than 200 ps for extremely short lifetimes to roughly 130 ps for
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lifetimes over 1 ns. As the IRF introduces a non-linear offset at very short lifetimes, the IRF
correction is based on this look-up table, rather than a fixed offset.
The final correction assumes τm ≡ τt and replaces the measured lifetime τm by the lifetime τ
corresponding to τt . In the remainder of this work “extracted lifetime” will always refer to the
lifetime after correction.
3. System calibration
The FluoCam’s lifetime extraction capability was characterised using ICG. This NIR fluores-
cence marker with sub-nanosecond lifetime properties was chosen because it is already ap-
proved for clinical use [10, 11]. The previously described set-up was used with a slightly de-
focused optics, in order to increase the statistics over more pixels in the array. The samples
targeted in this initial calibration phase were solutions of ICG diluted in water, milk (3.5% fat)
and blood (which is biologically more relevant). The concentrations of ICG in the solutions
ranged from 2 µM to 200 µM, under conditions similar to those employed in [29] to allow a
comparison of the results.
The most stable lifetime over different concentrations is provided by ICG in water, which
exhibits quite a short lifetime (ranging from 150 ps in [36], 166 ps in [29] and 170 ps in [37],
to 190 ps in [38] and 200 ps in [39]). On average a result around 170 ps for every molar
concentration is expected.
An example of the images provided by the FluoCam is shown in Fig. 7(a), with the intensity
profile, peaking over the laser illumination spot, drawn on top of a mostly uniform lifetime
image. Vertical stripes every 8 rows are due to a system readout artefact. Furthermore, some
rows (and pixels) were disabled as they were saturating or showing excessive noise.
In this case, the total photon flux sensed in the spot area, averaged over the whole acquisition
time (〈Φtot〉), is of about 3 · 107 cps, i.e. photons per second. The spot area is defined as all
pixels Ntot above the intensity threshold set during analysis. In this example there are about
900 pixels in the spot.
The signal-to-noise ratio (SNR) of the sample is defined, for photon counting imagers, as:
SNR ≡ 20 · log10
(
〈Φtot〉/Ntot√〈Φtot〉/Ntot +DCR
)
(6)
P
ix
el
 in
te
ns
ity
 [c
ps
]
0.5
1
1.5
2
x 105
(a)
0.05 0.5 1 1.5 2
x 105
400
450
500
550
600
650
700
750
800
Pixel intensity [cps]
E
xt
ra
ct
ed
 li
fe
tim
e 
[p
s] τ = 613 ps
σ = 8.1 ps
(b)
Fig. 7: Extracted lifetime and intensity for ICG diluted in milk (concentration: 25 µM). (a) Extracted lifetime
(3D bars) showing the uniform lifetime extraction ability with respect to the measured pixel intensity (top 2D
plane). (b) Scatter plot of the extracted lifetime versus pixel intensity. The lifetime oscillations with intensity
are likely due to a sub-optimal optical set-up, which slightly distorted the fluorescence signal. Their effect on
the average lifetime is minor.
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The SNR of the ICG in milk sample is for example 45 dB. Switching to ICG in vivo, the
SNR drops to less than 39 dB. Equation (6) approximates the theoretical best SNR achievable
in lifetime estimations [31]. A detailed derivation of the precision equation of the proposed
lifetime estimation methods can be obtained following the procedures published elsewhere [31,
32].
The sample’s overall lifetime is determined from the lifetimes extracted in each individual
pixel (Fig. 7(a)) by applying an intensity-weighted Gaussian fit to the corresponding distribu-
tion (Fig. 7(b)). The deviation from the resulting average lifetime can be seen to be determined
by the pixel SNR, whereby pixels with high intensity show less spread compared to those with
low intensity and thus low SNR.
Although the pixel SNR on the edges of the spot decreases, the extracted lifetime is stable
down to a signal intensity of roughly 4 kcps. Therefore the intensity threshold was set at 5 kcps,
ignoring pixels with a lower intensity, as their SNR is by experience too low for proper data
analysis. In this example, this results in an average τ of 613 ps with a standard deviation σ of
about 8 ps.
A second way to determine the SNR is directly from the sample’s lifetime [32] by applying
SNR′ ≡ 20 · log10
( τ
σ
)
(7)
which yields 38 dB (and 26 dB for the in vivo sample), confirming a lifetime extraction al-
gorithm induced SNR deterioration of several dB compared to the theoretical maximum SNR
obtained with Eq. (6) [31]. We will be using Eq. (6) to calculate all following SNR values,
indicating the maximum achievable SNR of the sample.
Figure 8(a) finally shows the extracted lifetime (as per Fig. 7) as a function of the ICG
concentration, in the three different media under analysis. The results acquired with both LSM
and CMM, ranging from 165 ps to 700 ps, are in very good agreement with those previously
reported in the literature [29]. The decrease in lifetime for higher concentrations, in the case
of milk and blood, is likely due to the quenching effect, and to a possible reabsorption of
the fluorescence photons by the dye itself [29]. The extraction performance over other delay
steps (N×12.3 ps), shown in Fig. 8(c), is obtained by ignoring the intermediate time steps from
measurements obtained with the minimum 12.3 ps step size. The resulting performance features
results similar to those obtained with a 1× delay step at least up to 8×. While the acquisition
time could therefore be reduced accordingly (to about 1-2 minutes), we preferred to carry out
all following acquisitions with the minimum time step, except where indicated otherwise.
4. In vitro measurements
In order to test the camera with biologically relevant samples, and as a mandatory step before
in vivo data acquisition, measurements were carried out with living cells cultured in vitro. We
studied a contrast agent specific for tumors, which targets the αvβ3 integrin. The αvβ3 integrin
is an attractive marker for diagnostic imaging of tumor angiogenesis due to its high expres-
sion on activated and proliferating endothelial cells during tumor angiogenesis and metastasis,
in contrast to resting endothelial cells and most normal organs. It is also expressed by many
tumors, such as metastatic melanoma and glioblastoma. The αvβ3 integrin is the receptor for
extracellular matrix proteins such as vitronectin, which binds to the integrin via an Arg-Gly-Asp
(RGD) peptide sequence [12, 40–42]. In order to target this receptor, mono-, di- and tetramer-
ic c(RGD f K) structures were conjugated to an ICG-modified derivative to yield, respectively,
ICG-c(RGD f K), ICG−E[c(RGD f K)2], and ICG−E[c(RGD f K)4] [13].
A first experiment consisted in measuring the mono- and dimeric RGD molecules dilut-
ed in milk at a same concentration of 20 µM, to compare the compounds to standard ICG.
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Fig. 8: (a) Extracted lifetime obtained with the algorithm proposed in Fig. 4 and a CMM algorithm, compared
with [29], and (b) spot SNR vs. ICG molar concentration in various media (water, milk and blood). (c) Extracted
lifetime and error obtained for different delay lines step sizes (N×12.3 ps) for three samples. Results from
literature have been interpolated to match the concentrations used in our measurements.
Figure 9 shows the scatter plots of extracted lifetimes versus pixel intensity for the three solu-
tions. The lifetime for standard ICG (607±5 ps) is about 60 ps lower than that measured with
ICG-c(RGD f K) and ICG−E[c(RGD f K)2], which are comparable (671±6 ps and 669±10 ps,
respectively).
The flux of photons sensed in the whole spot area was of 4.61 · 107, 2.22 · 107 and
1.21 ·107 cps, for standard ICG, ICG-c(RGD f K) and ICG−E[c(RGD f K)2], respectively, cor-
responding to SNR values of 44 dB, 42 dB and 40 dB, respectively.
All three measurements were carried out under the same conditions; the quantum yield de-
crease when moving from standard ICG to mono- and dimeric c(RGD f K) structures is likely
due to a packing effect, which leads to quenching of the fluorescence signal.
In vitro measurements were then carried out using ICG-c(RGD f K). Two cell lines were
studied: SK-MEL-37 melanoma cells, expressing αvβ3 integrin on the cell surface, and HEK-
293T embryonic kidney cells, negative for the marker (as assessed by flow cytometric analysis
with a specific antibody). Aliquots of cells (106) were incubated for 10 minutes at 37◦C in a
1% bovine serum albumin (BSA)/Hanks balanced salt solution containing ICG-c(RGD f K) at
concentrations from 5 µM up to 200 µM. Labeled cells were washed to remove unincorporated
dye and pelleted into wells of flat-bottom 96-well plates.
Figure 10(a) shows that the extracted time constants range from 370 ps to 510 ps. Cells
that express the αvβ3 integrin feature an equal (within the measurement errors, which affected
in particular the low concentration measurements) or higher lifetime, with the difference in-
creasing towards higher concentration values. Figure 10(b) shows the corresponding spot SNR
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Fig. 9: Comparison of extracted lifetimes for untargeted vs. targeted ICG in milk (concentration: 20 µM).
Fluorescent probes used: (a) ICG, (b) ICG−c(RGD f K), (c) ICG−E[c(RGD f K)2]. The targeted ICG shows a
lifetime about 60 ps higher than untargeted ICG.
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Fig. 10: Measurements of in vitro cultured melanoma cells expressing αvβ3 integrin (SK-MEL-37 cell line)
vs. melanoma cells not expressing αvβ3 integrin (HEK-293T embryonic kidney cells). (a) Extracted lifetime
and (b) spot SNR versus ICG-c(RGD f K) concentration.
results for the two cell lines, whereby cells expressing the αvβ3 integrin emit more fluorescence
photons (1.5-3×).
These preliminary in vitro measurements proved our capability of measuring lifetimes on bi-
ologically relevant samples, and provided an indication of the expected lifetimes in vivo (which
actually turned out to be quite comparable) when employing targeted ICG. However, one should
be careful with the interpretation of low-intensity measurements as the standard deviation get-
s larger with lower signals, and overall additional measurements are needed to derive firmer
conclusions.
5. In vivo measurements
5.1. Preliminary measurements
As a first step towards more clinically relevant data, the FluoCam was used to character-
ize ICG−E[c(RGD f K)4], in vivo. Tetrameric c(RGD f K) is potentially appealing due to it-
s higher affinity and also activity against integrins as compared to monomeric and dimeric
c(RGD f K) [43]. It also shows higher levels of internalization/endocytosis by the cell. On
the other hand, solubility can be an issue, the compound is more difficult to synthesize, and
tetrameric c(RGD f K) can tend to aggregate, thereby quenching the fluorescence signal.
In order to faithfully model a human tumor we used a genetically engineered mouse model
of melanoma [44], in which tumors were locally induced at the ears, by topically applying
4 hydroxy-tamoxifen. These tumors express high levels of αvβ3 integrin. The animals were
used at the EPFL (Ecole Polytechnique Fe´de´rale de Lausanne, Switzerland) in accordance with
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Fig. 11: (a) ICG−E[c(RGD f K)4] in vivo (melanoma mouse model) fluorescence intensity measured 24 hours
after injection with IVIS Spectrum and with (b) FluoCam targeted on the tumor (mouse ear), showing pho-
tobleaching in the brightest pixels during the 7 minutes acquisition time. No usable fluorescence signal was
detected elsewhere with the FluoCam.
local animal ethical regulations and under an approved animal license protocol (Protocol 2564).
Tumor bearing mice with 200 mm3 tumors were injected with ICG−E[c(RGD f K)4] in the tail
vein under general anesthesia. A total of 17 µg of ICG−E[c(RGD f K)4], dissolved in 100 µL
of phosphate buffer saline (PBS):dimethyl sulfoxide (DMSO) 2:1, was delivered.
The mouse was imaged with the FluoCam, on a station equipped with anesthesia and a heated
bed. Fluorescence lifetimes were measured 0.5 hour, 24 hours and 96 hours after administration
of the fluorescent probe. In addition, the mouse was imaged with a pre-clinical in vivo imaging
system (Perkin-Elmer IVIS Spectrum), which can only measure the fluorescence intensity.
The intensity image obtained by the IVIS imaging system 24 hours after injection (Fig. 11(a))
shows a 20 times higher fluorescence intensity at the ears of the mouse (tumor spot), than for
the background signal, demonstrating the excellent specificity of ICG−E[c(RGD f K)4] on the
targeted tumor. The same pattern was observed with the FluoCam (Table 2) for the spot SNR on
the mouse tumor. The SNR peaks roughly 24 hours after injection. The FluoCam data showed
a clear fluorescence signal when the laser spot was aimed at the tumor, but it disappeared when
any other region of the mouse was targeted.
The fluorescence lifetime was extracted for each pixel in the spot above the usual intensity
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Fig. 12: In vivo (melanoma mouse model) extracted lifetime and intensity on the mouse tumor (ear) 24 hours
after injection. (a) Extracted lifetime (3D bars) and measured pixel intensity (2D plane). (b) Scatter plot of the
extracted lifetime versus pixel intensity.
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Table 2: in vivo (melanoma mouse model) lifetime results for ICG−E[c(RGD f K)4], including with a simulated
4× delay step (results for two consecutive measurements M1/M2, whenever available).
Delay step size 1× Delay step size 4×
Target Time of measurement Extracted Lifetime error Extracted Lifetime error SNR
after injection lifetime τ [ps] σ [ps] lifetime τ [ps] σ [ps] [dB]
Solution Before 323 / 332 6 / 6 387 / 310 11 / 9 43
Tumor
0.5 hour 424 22 466 29 37
24 hours 508 / 516 29 / 26 503 / 500 29 / 30 39
96 hours 453 / 459 27 / 37 448 / 442 26 / 39 38
threshold at 5 kcps. For the tumor measurement 24 hours after injection of the probe, this
result is shown in Fig. 12. From the 1500 pixels above the threshold, the extracted lifetime was
516±26 ps. Despite mouse motion (breathing) and photobleaching (Fig. 11(b)), the extracted
lifetimes were very stable and reproducible in multiple measurements.
The complete set of measurement results are presented in Table 2, which includes a compar-
ison with the values which would have been obtained employing a 4× delay step. As reference,
the solution’s lifetime was measured before injection, and is of the order of 330 ps. 0.5 hour
after injection, the ICG starts to be bound to the tumor and the lifetime increases to 424 ps.
24 hours after injection, when the intensity peaks and the tumor-to-background ratio was
maximal, the lifetime was around 512 ps. After 24 hours the signal degraded and both intensity
and lifetime decreased; the fluorescent probe is washed out and becomes unbound. However,
the lifetime signal is still detectable 96 hours after injection.
This data demonstrated the feasibility of performing reproducible in vivo measurements,
including over long time spans. Also, a good cross-correlation was found with the IVIS intensity
images. However, there is a need to differentiate bound from unbound c(RGD f K) in vivo, at the
same moment in time, to achieve a clinically relevant system. Therefore we conducted a second
in vivo, larger series of experiments using a higher dose of the monomeric fluorescent probe
version (easier to synthesize) in order to enable measurements both in tumor and adjacent,
normal (control) tissue.
5.2. Additional measurements
Animal experiments were performed in 6-8 week-old a-tymic female mice (CD1-Fox1nu,
Charles River Laboratories, l’Arbresle, France), weighing 25-35 g. The mice were provided
with autoclaved low fluorescence pellet food, normal pellet food and sterilized water ad li-
bitum. Experiments were approved by the Animal Welfare Committee of Leiden University
Medical Center, The Netherlands.
Tumor inoculation and lifetime measurements were performed under isoflurane gas anesthe-
sia (4% induction and 2% maintenance). Four subcutaneous tumors on the back were induced
by injection of U87-MG cells (1.5− 3.0 · 106 cells per site) - a human primary glioblastoma
cell line, expressing high levels of αvβ3. When tumors were grown, 30 nmol (50 µg) of ICG-
c(RGD f K), dissolved in PBS, was injected intravenously. This corresponds to approximatively
12 times as many tracer molecules as in the previously described experiments with tetrameric
c(RGD f K) (3×weight increase and 1:4 molecular weight ratio). For the tail, a small additional
ICG-c(RGD f K) bolus was injected subcutaneously to create a pocket of unbound probe.
Fluorescent lifetimes were measured at the tail, muscle, and tumor both 0.5-2.5 hours and
24 hours after injection. Measurements were taken with the default 1× delay step as well as
with 4× delay steps to reduce the acquisition time.
The variance between groups was first assessed via one way analysis of variation; differences
in means between two groups were assessed via the post-hoc Bonferroni test. p < 0.05 was
considered statistically significant.
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Fig. 13: ICG-c(RGD f K) in vivo (glioblastoma mouse model) fluorescence lifetime and spot SNR measure-
ments. The injected concentration of ICG-c(RGD f K) is 30 nmol (50 µg). (a) Extracted lifetimes for mouse
tumor (bound), muscle (partially bound) and tail (unbound fluorophore), both 0.5-2.5 and 24 hours after injec-
tion. (b) Signal-to-Noise ratio both 0.5-2.5 and 24 hours after injection.
In total 42 measurements (30 with delay step 1× and 12 with 4× delay steps) were taken in
two mice: 15 at the tail, 8 at muscle tissue, and 19 at tumor tissue. Only from one measurement
no lifetime could be extracted due to too low SNR. Figure 13(a) shows the resulting extracted
lifetimes. Lifetimes in both tail (n = 9; 480± 36 ps) and muscle (n = 6; 468± 16 ps) were
significantly lower than in tumor (n = 11; 515±15 ps) 0.5-2.5 hours after injection (p = 0.011
and p = 0.003, respectively), while tail and muscle lifetimes did not differ significantly. No
significant differences were found between the tissue types 24 hours after injection, nor over
time at a given location. Figure 13(b) shows the signal-to-noise ratio. Due to the bolus injection
at the tail, the spot SNR was there almost 6 dB higher than at the tumor, whereas the lowest
spot SNR was seen at the muscle, as much less αvβ3 is present there. Finally, the spot SNR at
the tumor site decreases significantly (3 dB) 24 hours after injection, whereas it stays nearly
constant at the other sites.
These preliminary measurements indicate that our system is able to capture the subtle lifetime
differences between bound and unbound probe in vivo. As αvβ3 is highly expressed in tumor
tissue and not present in the tail bolus, bound probe is mostly present in tumor, and unbound
probe in tail. For muscle tissue, a combination of bound and unbound probe probably applies,
as αvβ3 is present in blood vessels, but not as abundantly as in tumor tissue. We observe that
the lifetime of the bound probe is significantly higher than that of the unbound probe. Although
the number of measurements is limited, it is encouraging that unbound and bound probe can be
differentiated, even more so as these differences are measurable shortly after injection.
6. Conclusion and outlook
We have shown that the proposed SPAD-based FluoCam, resulting from the integration of
an existing single-photon SPSD imager with a precise gating scheme and innovative signal
processing and lifetime calculation approaches, allows the complete fine reconstruction of a
fluorescence signal and is capable of deriving sound fluorescence intensity and lifetime data
for ICG-modified derivatives, in particular those conjugated with cyclic pentapeptide targeting
the αvβ3 integrin. Its sensitivity, albeit at present low in absolute terms and therefore entailing
long acquisition times, is sufficient to derive sub-nanosecond lifetimes in good agreement with
literature, as well as to carry out measurements in vivo.
FluoCam’s signal processing capabilities, as well as its IRF and precise gating control, which
are at a comparable level with other existing time-gated solid state FLIM sensors [45–47], did
eventually enable true in vivo discrimination of the subtle lifetime differences between bound
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and unbound ICG-modified fluorophores (10% level in our case).
The FluoCam will therefore be used to perform further biological experiments, including
extensive in vivo studies. In parallel we will be working on improving its performance, towards
our goal of designing a next-generation real-time SPAD-based instrument to study how the
lifetime information could improve fluorescence-guided surgical procedures in the operating
theatre. This activity focuses on the one hand on the improvement of the fill-factor at the pixel
level - to bring it on par with other existing solid-state FLIM sensors [45–47] - and on the photon
detection probability increase in the near infrared [48], on the other hand on the implementation
of more photon-efficient architectures such as TCSPC [49]. We believe that these results are
within reach, in particular by migrating to more advanced CMOS technology nodes and/or 3D
stacking approaches, thus paving the way to the clinical use of fluorescence lifetime data.
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